CD300f As A Novel Therapeutic Antibody Target in Acute Myeloid Leukaemia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1055892

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

This study aims to develop a new antibody therapy for Acute Myeloid Leukaemia (AML), the most common type of leukaemia in adults. We will study the function of CD300f, a new receptor found on the surface of both healthy blood cells and the cancer cells in AML. We will investigate whether blocking this receptor with a newly developed antibody can be used to kill cancer cells. It is hoped that this study will allow development of this antibody for use in a future clinical trial.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2015

Funding Scheme: Postgraduate Scholarships

Funding Amount: $89,926.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Haematological Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibody cancer therapy | cell surface receptor | immune modulation | leukocytes | myeloid leukaemia

Related Links